Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5	"909012".ap.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 15:55
L2	5684	"Hepatitis C virus"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:00
L3	1115	"Hepatitis C virus" and protease with inhibitor	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:00
L4	251	"Hepatitis C virus" and serine with protease with inhibitor	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:00
L5	120	"Hepatitis C virus" same serine with protease with inhibitor	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:00
L6	110	"Hepatitis C virus" same serine with protease with inhibitor and NS3	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:01
L7	105	"Hepatitis C virus" same NS3 with serine with protease with inhibitor	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:02
L8	105	"Hepatitis C virus" same NS3 with serine with protease with inhibitor and compound	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:02
L9	88	l8 and pharmaceutical	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:02
L10	76	l8 and pharmaceutical and assay	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:02
L11	11	l8 and pharmaceutical and assay and "Ki value"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/02/23 16:03

23/02/200516:17Print selected from Online session

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653rbm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS	19	FEB 16	STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

23/02/200516:17Print selected from Online session

```
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:11:58 ON 23 FEB 2005

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
       BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
       CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 16:12:17 ON 23 FEB 2005

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> "Hepatitis C virus" and  NS3 and serine and protease and inhibitor and compound
          6   FILE ADISINSIGHT
          1   FILE BIOENG
         23   FILE BIOSIS
          4   FILE BIOTECHABS
          4   FILE BIOTECHDS
          9   FILE BIOTECHNO
  15 FILES SEARCHED...
          1   FILE CANCERLIT
         64   FILE CAPLUS
         31   FILE DDFU
  26 FILES SEARCHED...
        335   FILE DGENE
  27 FILES SEARCHED...
         44   FILE DRUGU
         60   FILE EMBASE
         15   FILE ESBIOBASE
  35 FILES SEARCHED...
          1   FILE GENBANK
         43   FILE IFIPAT
          1   FILE JICST-EPLUS
         10   FILE LIFESCI
  49 FILES SEARCHED...
         33   FILE MEDLINE
         19   FILE PASCAL
          7   FILE PHAR
          1   FILE PHARMAML
          4   FILE PROMT
  61 FILES SEARCHED...
         82   FILE PROUSDDR
         26   FILE SCISEARCH
          1   FILE SYNTHLINE
         11   FILE TOXCENTER
        329   FILE USPATFULL
         39   FILE USPAT2
```

```
        48   FILE WPIDS
  73 FILES SEARCHED...
         2   FILE WPIFV
        48   FILE WPINDEX

  31 FILES HAVE ONE OR MORE ANSWERS,   75 FILES SEARCHED IN STNINDEX

L1    QUE "HEPATITIS C VIRUS" AND NS3 AND SERINE AND PROTEASE AND INHIBITOR AND
      COMPOUND

=> d rank
F1          335   DGENE
F2          329   USPATFULL
F3           82   PROUSDDR
F4           64   CAPLUS
F5           60   EMBASE
F6           48   WPIDS
F7           48   WPINDEX
F8           44   DRUGU
F9           43   IFIPAT
F10          39   USPAT2
F11          33   MEDLINE
F12          31   DDFU
F13          26   SCISEARCH
F14          23   BIOSIS
F15          19   PASCAL
F16          15   ESBIOBASE
F17          11   TOXCENTER
F18          10   LIFESCI
F19           9   BIOTECHNO
F20           7   PHAR
F21           6   ADISINSIGHT
F22           4   BIOTECHABS
F23           4   BIOTECHDS
F24           4   PROMT
F25           2   WPIFV
F26           1   BIOENG
F27           1   CANCERLIT
F28           1   GENBANK
F29           1   JICST-EPLUS
F30           1   PHARMAML
F31           1   SYNTHLINE


=> file caplus ROUSDDR medline biosis
'ROUSDDR' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               3.54       3.75

FILE 'CAPLUS' ENTERED AT 16:15:49 ON 23 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

23/02/200516:17Print selected from Online session

FILE 'MEDLINE' ENTERED AT 16:15:49 ON 23 FEB 2005

FILE 'BIOSIS' ENTERED AT 16:15:49 ON 23 FEB 2005
Copyright (c) 2005 The Thomson Corporation.

=> "Hepatitis C virus" and NS3 and serine and protease and inhibitor and compound and pharmaceutical and assay
L2 7 "HEPATITIS C VIRUS" AND NS3 AND SERINE AND PROTEASE AND INHIBITO
R AND COMPOUND AND PHARMACEUTICAL AND ASSAY

=> d ti 1-7

L2 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
TI Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

L2 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
TI Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

L2 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
TI Preparation of nucleoside derivatives as **inhibitors** of RNA-dependent RNA viral polymerase

L2 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
TI Preparation of macrocyclic **NS3-serine protease inhibitors** of **hepatitis C virus** comprising alkyl and aryl alanine p2 moieties

L2 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
TI Pentacyclic **compounds** useful as **inhibitors** of **hepatitis C virus NS3** helicase

L2 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
TI Preparation of peptide analogs as **inhibitors** of **serine proteases**, particularly **hepatitis C virus NS3 protease**

L2 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
TI Prime site binding **inhibitors** of a **serine protease**: **NS3**/4A of **hepatitis C virus**.

=> d ab bib 1-7

L2 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N,

alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease. Thus, peptide II was prepared by the solid-phase method and showed Ki = 1-100 nM (category A) in the HCV continuous assay.

AN 2003:912843 CAPLUS
DN 139:381756
TI Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
IN Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; Mccormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua
PA USA
SO U.S. Pat. Appl. Publ., 629 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003216325	A1	20031120	US 2001-908955	20010719
	US 2004254117	A9	20041216		
	ZA 2002010312	A	20040329	ZA 2002-10312	20021219
PRAI	US 2000-220108P	P	20000721		

OS MARPAT 139:381756

L2 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is selected from O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease. Thus, peptide II was prepared and showed Ki = 1-100 nM (category A) in the HCV continuous assay.

AN 2003:591204 CAPLUS
DN 139:149928
TI Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
IN Saksena, Anil K.; Girijavallabhn, Viyyoor M.; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell

E.; Bogen, Stephane L.; Chan, Tin-yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, George F.; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Wong, Jesse K.; Nair, Latha G.

PA Schering Corporation, USA; Corvas International, Inc.; Dendreon Corp.

SO PCT Int. Appl., 633 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062265	A2	20030731	WO 2003-US1430	20030116
	WO 2003062265	A3	20040916		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1481000	A2	20041201	EP 2003-731956	20030116
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-52386	A	20020118		
	WO 2003-US1430	W	20030116		

OS MARPAT 139:149928

L2 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB The present invention provides nucleoside **compds**. I, wherein R1 is alkenyl, alkynyl, alkyl, wherein alkyl is unsubstituted or substituted with hydroxy, amino, alkoxy, alkylthio, one to three fluorine atoms; R2 is hydrogen, fluorine, hydroxy, mercapto, alkoxy, alkyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered saturated monocyclic ring system optionally containing a heteroatom selected from O, S, and NC-alkyl; R3 and R4 are each independently hydrogen, cyano, azido, halogen, hydroxy, mercapto, amino, alkoxy, alkenyl, alkynyl, alkyl; R5 is hydrogen, alkylcarbonyl, phosphate; R6 and R7 are each independently hydrogen, Me, hydroxymethyl, or fluoromethyl; R8 is hydrogen, alkyl, alkynyl, halogen, cyano, carboxy, alkyloxycarbonyl, azido, amino, alkylamino, di(alkyl)amino, hydroxy, alkoxy, alkylthio, alkylsulfonyl, alkylaminomethyl, cycloheteroalkyl; R9 is hydrogen, cyano, nitro, alkyl, NHCONH2, amide, thioamide, ester, C(=NH)NH2, hydroxy, alkoxy, amino, alkylamino, di(alkyl)amino, halogen, (1,3-oxazol-2-yl), (1,3-thiazol-2-yl), or (imidazol-2-yl); R10 and R11 are each independently hydrogen, hydroxy, halogen, alkoxy, amino, alkylamino, di(alkyl)amino, cycloalkylamino, di(cycloalkyl)amino, cycloheteroalkyl, and certain derivs. thereof which are **inhibitors** of RNA-dependent RNA viral polymerase. These **compds**. are **inhibitors** of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as **inhibitors** of **hepatitis C virus** (HCV) NS5B polymerase, as **inhibitors** of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes **pharmaceutical** compns. containing such nucleoside **compds**.

alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside **compds**. of the present invention. Thus, 4-amino-7-(2-C-methyl-β-D-arabinofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine was prepared as **inhibitors** of RNA-dependent RNA viral polymerase. Representative **compds**. tested in the HCV NS5B polymerase **assay** exhibited IC's less than 100 μM. The nucleoside derivs. were also screened for cytotoxicity against cultured hepatoma (HuH-7) cells containing a sub-genomic HCV Replicon in an MTS cell-based **assay**.

AN 2002:555511 CAPLUS
DN 137:109450
TI Preparation of nucleoside derivatives as **inhibitors** of RNA-dependent RNA viral polymerase
IN Carroll, Steven S.; Maccoss, Malcolm; Olsen, David B.; Bhat, Balkrishen; Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.; Prakash, Thazha P.; Prhavc, Marija; Song, Quanlai
PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002057287	A2	20020725	WO 2002-US3086	20020118
	WO 2002057287	A3	20021010		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2434386	AA	20020825	CA 2002-2434386	20020118
	US 2002147160	A1	20021010	US 2002-52318	20020118
	US 6777395	B2	20040817		
	EE 200300338	A	20031015	EE 2003-338	20020118
	EP 1355916	A2	20031029	EP 2002-709299	20020118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002006614	A	20040217	BR 2002-6614	20020118
	JP 2004520367	T2	20040708	JP 2002-557963	20020118
	NZ 526703	A	20041224	NZ 2002-526703	20020118
	US 2004072788	A1	20040415	US 2003-431657	20030507
	ZA 2003005078	A	20040521	ZA 2003-5078	20030630
	BG 108000	A	20040831	BG 2003-108000	20030717
	NO 2003003289	A	20030919	NO 2003-3289	20030721
	US 2004067901	A1	20040408	US 2003-688691	20031017
PRAI	US 2001-263313P	P	20010122		
	US 2001-282069P	P	20010406		
	US 2001-299320P	P	20010619		
	US 2001-344528P	P	20011025		
	US 2002-52318	A3	20020118		
	WO 2002-US3086	W	20020118		

23/02/200516:17Print selected from Online session

OS MARPAT 137:109450

L2 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB Macrocyclic **compds**. I [E, X, Y may be independently present or absent, and if present may be (un)substituted (cyclo)alkyl, aryl, heteroalkyl, heteroaryl, ether, amino, sulfide, sulfone, amide, sulfonamide, urea, carbamate, hydrazide, carbonyl, etc.; R1 = acyl or boryl groups; Z = O, N, or CH; W = null, CO, CS, SO2, C:NR (R = H, alkyl, cycloalkyl, aryl, etc.); Q = (NR)p (p = 0-6), O, S, CH2, CHR, CRR' (R' = any group given for R) or a double bond toward V; A = O, CH2, (CHR)p, (CHRCHR')p, (CRR')p, NR, S, SO2, CO or a bond; G = (CH2)p, (CHR)p, (CRR')p, NR, O, S, SO2, SO2NH, CO or a bond towards E or V; R2, R3, R4 = H, (un)substituted (hetero)alkyl, -aryl or -cycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, etc.], including enantiomers and pharmaceutically acceptable salts, were prepared as **hepatitis C virus** (HCV) **protease inhibitors**. Thus, peptide II was prepared by a multistep procedure involving cyclization of intermediate cyclopentadiene-η6-ruthenium-4-chlorophenylpropionic acid-cyclohexylglycine-m-tyrosine-OMe. II showed Ki = 0.001-1.0μM in the HCV **protease assay**. The invention also discloses **pharmaceutical** compns. comprising I as well as methods of using them to treat disorders associated with the HCV **protease**.

AN 2001:798207 CAPLUS

DN 135:344735

TI Preparation of macrocyclic **NS3-serine protease inhibitors** of **hepatitis C virus** comprising alkyl and aryl alanine p2 moieties

IN Venkatraman, Srikanth; Chen, Kevin X.; Arasappan, Ashok; Njoroge, F. George; Girijavallabhan, Viyyoor M.; Chan, Tin-Yau; McKittrick, Brian A.; Prongay, Andrew J.; Madison, Vincent S.

PA Schering Corporation, USA

SO PCT Int. Appl., 218 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081325	A2	20011101	WO 2001-US12530	20010417
	WO 2001081325	A3	20020801		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2406532	AA	20011101	CA 2001-2406532	20010417
	US 2002016294	A1	20020207	US 2001-836636	20010417
	BR 2001010104	A	20030107	BR 2001-10104	20010417
	EP 1274724	A2	20030115	EP 2001-927142	20010417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003531199	T2	20031021	JP 2001-578418	20010417
	NZ 521456	A	20040730	NZ 2001-521456	20010417
	ZA 2002008014	A	20040212	ZA 2002-8014	20021004

	NO 2002005030	A	20021218	NO 2002-5030	20021018
PRAI	US 2000-198204P	P	20000419		
	WO 2001-US12530	W	20010417		

OS MARPAT 135:344735

L2 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB A series of 2,3,5-trisubstituted-1,2,4-thiadiazol-2-ium salts is reported by Vertex **Pharmaceuticals** to possess inhibitory properties against **NS3**, a multifunctional (**serine protease** and NTPase/helicase) protein of **hepatitis C virus** (HCV), the causative agent of non-A, non-B hepatitis. These **compds**. were prepared by simple synthetic procedures and assayed in vitro for their inhibitory properties of different enzymic activity of **NS3**, such as the unwinding **assay**, the spectrophotometric ATPase **assay**, as well as the HPLC ATPase activity **assay**. Some of them showed in vitro inhibitory activity in the low micromolar range, making them interesting leads for the development of more efficient HCV helicase **inhibitors**. No in vivo data are presented.

AN 2000:799386 CAPLUS

TI Pentacyclic **compounds** useful as **inhibitors** of **hepatitis C virus NS3** helicase

AU Anon.

SO Expert Opinion on Therapeutic Patents (2000), 10(11), 1777-1779
CODEN: EOTPEG; ISSN: 1354-3776

PB Ashley Publications Ltd.

DT Journal

LA English

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB The present invention relates to **compds**. I [G1 = SH, OH, SMe, alkenyl, alkynyl, CF3, C1-2 alkoxy, C1-2 alkylthio, (un)substituted C1-3 alkyl; W1 = COCF2CH2N(G4)U, CHO, COG2, COCF2CF3, COCOG2, COCO2G2, B(Q1)2; G2 = alkyl, aryl, aralkyl, (un)substituted mono-, bi-, or tricyclic heterocycle; G4 = alky, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, etc.; Q1 = OH, alkoxy, aryloxy, or Q1-Q1 form a 5-7 membered ring; U = H, G9CO, G9SO2, G9COCO, (G9)2NCOCO, (G9)2NSO2, (G9)2NCO, G9O2C; G9 = H, alkyl, carboxyalkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, heterocycloalkyl, etc; or G9-G9 form a ring; E4 = bond, α-amino acid residue, heterocyclic amino acid; E5-E8 = independently bond, amino acid residue; 1-2 peptide bonds between E5-E8 may be reduced], methods and **pharmaceutical** compns. for inhibiting **proteases**, particularly **serine proteases**, and more particularly HCV **NS3 proteases**. The **compds**., and the compns. and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus. Thus, peptide aldehyde II was prepared using solid-phase methods on a benzhydrylamine resin and tert-butoxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) protection starting from protected hydrazone III. Nearly 200 **compds**. I were prepared and tested for **hepatitis C virus NS3 protease** inhibitory activity, with II exhibiting Ki <1 μM in an in vitro **assay**.

AN 1998:268513 CAPLUS

DN 128:321945

TI Preparation of peptide analogs as **inhibitors** of **serine proteases**, particularly **hepatitis C**

virus NS3 protease

IN Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

PA Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9817679	A1	19980430	WO 1997-US18968	19971017
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2268391	AA	19980430	CA 1997-2268391	19971017
	ZA 9709327	A	19980511	ZA 1997-9327	19971017
	AU 9851477	A1	19980515	AU 1998-51477	19971017
	AU 719984	B2	20000518		
	EP 932617	A1	19990804	EP 1997-946273	19971017
	EP 932617	B1	20020116		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	IN 183120	A	19990911	IN 1997-CA1951	19971017
	BR 9712544	A	19991019	BR 1997-12544	19971017
	CN 1238780	A	19991215	CN 1997-180151	19971017
	CN 1133649	B	20040107		
	NZ 335276	A	20000929	NZ 1997-335276	19971017
	JP 2001502694	T2	20010227	JP 1998-519568	19971017
	EP 1136498	A1	20010926	EP 2001-109433	19971017
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AP 1019	A	20011016	AP 1999-1512	19971017
	W: GH, KE, LS, MW, SD, SZ, UG, ZW				
	AT 212037	E	20020215	AT 1997-946273	19971017
	ES 2169880	T3	20020716	ES 1997-946273	19971017
	EE 4023	B1	20030415	EE 1999-161	19971017
	TW 530065	B	20030501	TW 1997-86115382	19971018
	NO 9901832	A	19990617	NO 1999-1832	19990416
	US 6265380	B1	20010724	US 1999-293247	19990416
	KR 2000049263	A	20000725	KR 1999-703372	19990417
	HK 1023779	A1	20020927	HK 2000-100690	20000203
	US 2002032175	A1	20020314	US 2001-875390	20010606
	US 6617309	B2	20030909		
	US 2004266731	A1	20041230	US 2003-607716	20030627
PRAI	US 1996-28290P	P	19961018		
	EP 1997-946273	A3	19971017		
	WO 1997-US18968	W	19971017		
	US 1999-293247	A	19990416		
	US 2001-875390	A3	20010606		

OS MARPAT 128:321945

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

AB **Serine proteases** are the most studied class of proteolytic enzymes and a primary target for drug discovery. Despite the large number of **inhibitors** developed so far, very few make contact with the prime site of the enzyme, which constitutes an almost untapped opportunity for drug design. In the course of our studies on the **serine protease NS3**/4A of **hepatitis C virus** (HCV), we found that this enzyme is an excellent example of both the opportunities and the challenges of such design. We had previously reported on two classes of peptide **inhibitors** of the enzyme: (a) product **inhibitors**, which include the P6-P1 region of the substrate and derive much of their binding energy from binding of their C-terminal carboxylate in the active site, and (b) decapeptide **inhibitors**, which span the S6-S4' subsites of the enzyme, whose P2'-P4' tripeptide fragment crucially contributes to potency. Here we report on further work, which combined the key binding elements of the two series and led to the development of **inhibitors** binding exclusively to the prime site of **NS3**/4A. We prepared a small combinational library of tripeptides, capped with a variety of constrained and unconstrained diacids. The SAR was derived from multiple analogues of the initial micromolar lead. Binding of the **inhibitor**(s) to the enzyme was further characterized by circular dichroism, site-directed mutagenesis, a probe displacement **assay**, and NMR to unequivocally prove that, according to our design, the bound **inhibitor**(s) occupies (occupy) the S' subsite and the active site of the **protease**. In addition, on the basis of the information collected, the tripeptide series was evolved toward reduced peptide character, reduced molecular weight, and higher potency. Beyond their interest as HCV antivirals, these **compounds** represent the first example of prime site **inhibitors** of a **serine protease**. We further suggest that the design of an **inhibitor** with an analogous binding mode may be possible for other **serine proteases**.

AN 2002:315158 BIOSIS

DN PREV200200315158

TI Prime site binding **inhibitors** of a **serine protease**: **NS3**/4A of **hepatitis C virus**.

AU Ingallinella, Paolo; Fattori, Daniela; Altamura, Sergio; Steinkuhler, Christian; Koch, Uwe; Cicero, Daniel; Bazzo, Renzo; Cortese, Riccardo; Bianchi, Elisabetta; Pessi, Antonello [Reprint author]

CS Biopolymers Laboratory, Department of Molecular and Cell Biology, IRBM P. Angeletti, Via Pontina Km 30.600, 00040, Pomezia (Rome), Italy antonello_pessi@merck.com

SO Biochemistry, (April 30, 2002) Vol. 41, No. 17, pp. 5483-5492. print. CODEN: BICHAW. ISSN: 0006-2960.

DT Article

LA English

ED Entered STN: 29 May 2002
Last Updated on STN: 29 May 2002

Mondesi
09/909012

(FILE 'REGISTRY' ENTERED AT 16:12:00 ON 17 FEB 2005)

L3 STR



Page 1-A

~CO2H
21

Page 1-B

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 33
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE
L5 35 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 715 ITERATIONS 35 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'CAPLUS' ENTERED AT 16:17:37 ON 17 FEB 2005)
L6 1 S L5

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:90007 CAPLUS
DOCUMENT NUMBER: 136:151439
TITLE: Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Liu, Yi-Tsung; Chan, Tin-Yau; Zhu, Zhaoning; Arasappan, Ashok; Chen, Kevin X.; Venkatraman, Srikanth; Parekh, Tejal N.; Pinto, Patrick A.; Santhanam, Bama; Njoroge, F. George; Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.
PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.

SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008187	A1	20020131	WO 2001-US22813	20010719
WO 2002008187	C2	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2410682	AA	20020131	CA 2001-2410682	20010719
US 2002160962	A1	20021031	US 2001-909012	20010719
EP 1303487	A1	20030423	EP 2001-959041	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012666	A	20030610	BR 2001-12666	20010719
JP 2004513881	T2	20040513	JP 2002-514094	20010719
NZ 523781	A	20041029	NZ 2001-523781	20010719
ZA 2002010311	A	20040319	ZA 2002-10311	20021219
NO 2003000271	A	20030318	NO 2003-271	20030120
PRIORITY APPLN. INFO.:			US 2000-220107P P	20000721
			WO 2001-US22813 W	20010719

OTHER SOURCE(S): MARPAT 136:151439
GI



I



II

AB Novel peptides I [G, J, Y = independently H, alkyl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkoxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkyl-arylamino, arylamino, heteroarylamino, cycloalkylamino, and heterocycloalkylamino; Z = O, N, CH; W = null, CO, CS, SO2; R1 = COR5, B(OR)2; R5 = H, OH, OR8, NR9R10, CF3, C2F5, C3F7, CF2R6, R6, COR7; R7 = H, OH, OR8, CHR9R10, NR9R10; R6, R8-10 = independently H, alkyl, aryl, heteroalkyl, cycloalkyl, arylalkyl, peptide derivative, etc.; R, R2-4 = independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, etc.] and their pharmaceutically salts which have hepatitis C virus (HCV) protease inhibitory activity were prepared via solution or solid-phase peptide coupling methods. Thus, peptide II was prepared using solid-phase methods and showed a Ki value in the range of 0-100 nM for HCV protease inhibitory activity. This invention also discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease.

IT **393580-17-1P 393580-18-2P 393580-25-1P**
393580-27-3P 393580-30-8P 393580-34-2P
393580-36-4P 393580-37-5P 393580-38-6P
393580-42-2P 393580-43-3P 393580-44-4P
393580-45-5P 393580-46-6P 393580-47-7P
393580-48-8P 393580-49-9P 393580-50-2P
393580-51-3P 393580-52-4P 393580-53-5P
393580-54-6P 393580-56-8P 393580-62-6P
393580-80-8P 393582-07-5P 393582-08-6P
393582-28-0P 393582-29-1P 393582-30-4P
393582-31-5P 393582-32-6P 393582-57-5P
393582-58-6P 394203-67-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393580-17-1 CAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4-chloro-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-18-2 CAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4-fluoro-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-25-1 CAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-5-methyl-2-oxohexanoyl-2-13C-glycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-27-3 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-30-8 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-[1,1'-biphenyl]-4-yl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-34-2 CAPLUS
CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dithian-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-36-4 CAPLUS
CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dithiolan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-37-5 CAPLUS
CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-[1-[[2-(trimethylsilyl)ethoxy]carbonyl]-4-piperidinyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—SiMe3

RN 393580-38-6 CAPLUS
CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-(4-piperidinyl)glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-42-2 CAPLUS
CN Glycine, (2S)-2-[1-[(9H-fluoren-9-ylmethoxy)carbonyl]-4-piperidinyl]-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 393580-43-3 CAPLUS
CN Glycine, (2S)-2-(1-benzoyl-4-piperidinyl)-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-44-4 CAPLUS
CN Glycine, (2S)-2-[1-(4-carboxybenzoyl)-4-piperidinyl]-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CO_2H

RN 393580-45-5 CAPLUS
CN Glycine, (2S)-2-[1-[4-(aminosulfonyl)benzoyl]-4-piperidinyl]-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 393580-46-6 CAPLUS
CN Glycine, (2S)-2-(1-acetyl-4-piperidinyl)-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-47-7 CAPLUS
CN Glycine, (2S)-2-[1-(3,3-dimethyl-1-oxobutyl)-4-piperidinyl]-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-48-8 CAPLUS
CN Glycine, (2S)-2-[1-(cyclohexylacetyl)-4-piperidinyl]-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CO_2H

RN 393580-49-9 CAPLUS
CN Glycine, (2S)-2-[1-(cyclopentylcarbonyl)-4-piperidinyl]-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-50-2 CAPLUS
CN Glycine, (2S)-2-[1-[(acetylamino)acetyl]-4-piperidinyl]-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-51-3 CAPLUS
CN Glycine, (2S)-2-[1-[(2S)-4-methyl-2-[(methylsulfonyl)amino]-1-oxopentyl]-4-piperidinyl]-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-52-4 CAPLUS
CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-53-5 CAPLUS
CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,5-dihydro-2,4-benzodithiepin-3-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-54-6 CAPLUS
CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-56-8 CAPLUS
CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxolan-

2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-62-6 CAPLUS
CN Glycine, (2S)-2-cyclopentyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-80-8 CAPLUS
CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-dihydroxynorvalyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393582-07-5 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(3-methoxy-2,2-dimethyl-3-

oxopropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-08-6 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-28-0 CAPLUS
CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-L-leucyl-3-amino-5-methyl-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-29-1 CAPLUS
CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-(1,3-dithiolan-2-yl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-30-4 CAPLUS
CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-cyclopropyl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-31-5 CAPLUS
CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-(1,3-dioxolan-2-yl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-32-6 CAPLUS
CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-(1,3-dioxan-2-yl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-57-5 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclobutyl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-58-6 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-O-phenyl-L-homoseryl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394203-67-9 CAPLUS
CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-(tetrahydro-1-oxido-2H-thiopyran-4-yl)glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'CAOLD' ENTERED AT 16:18:17 ON 17 FEB 2005
L7 0 S L5

FILE 'USPATFULL' ENTERED AT 16:18:27 ON 17 FEB 2005
L8 1 S L5

L8 ANSWER 1 OF 1 USPATFULL on STN
ACCESSION NUMBER: 2002:288093 USPATFULL
TITLE: Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K., Upper Montclair, NJ, UNITED STATES
Girijavallabhan, Viyyoor Moopil, Parsippany, NJ, UNITED STATES
Bogen, Stephane L., Somerset, NJ, UNITED STATES

Searcher : Shears 571-272-2528

Lovey, Raymond G., West Caldwell, NJ, UNITED STATES
Jao, Edwin E., Warren, NJ, UNITED STATES
Bennett, Frank, Piscataway, NJ, UNITED STATES
Mc Cormick, Jinping L., Edison, NJ, UNITED STATES
Wang, Haiyan, Cranbury, NJ, UNITED STATES
Pike, Russell E., Stanhope, NJ, UNITED STATES
Liu, Yi-Tsung, Morris Township, NJ, UNITED STATES
Chan, Tin-Yau, Edison, NJ, UNITED STATES
Zhu, Zhaoning, East Windsor, NJ, UNITED STATES
Arasappan, Ashok, Bridgewater, NJ, UNITED STATES
Chen, Kevin X., Iselin, NJ, UNITED STATES
Venkatraman, Srikanth, Fords, NJ, UNITED STATES
Parekh, Tejal, Mountain View, CA, UNITED STATES
Pinto, Patrick A., Morris Plains, NJ, UNITED STATES
Santhanam, Bama, Bridgewater, NJ, UNITED STATES
Njoroge, F. George, Warren, NJ, UNITED STATES
Ganguly, Ashit K., Upper Montclair, NJ, UNITED STATES
Vaccaro, Henry A., South Plainfield, NJ, UNITED STATES
Kemp, Scott Jeffrey, San Diego, CA, UNITED STATES
Levy, Odile Esther, San Diego, CA, UNITED STATES
Lim-Wilby, Marguerita, La Jolla, CA, UNITED STATES
Tamura, Susan Y., Santa Fe, NM, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160962	A1	20021031
APPLICATION INFO.:	US 2001-909012	A1	20010719 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220107P	20000721 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 2831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 16:18:46 ON 17 FEB 2005)
L9 0 S L5

(FILE 'MARPAT' ENTERED AT 16:19:02 ON 17 FEB 2005)
L10 STR



Page 1-A

~CO2H
21

Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 24 33
GGCAT IS MCY UNS AT 33
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L12 1 SEA FILE=MARPAT SSS FUL L10 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 5620 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.14

L12 ANSWER 1 OF 1 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 136:151439 MARPAT
TITLE: Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Liu, Yi-Tsung; Chan, Tin-Yau; Zhu, Zhaoning; Arasappan, Ashok; Chen, Kevin X.; Venkatraman, Srikanth; Parekh, Tejal N.; Pinto, Patrick A.; Santhanam, Bama; Njoroge, F. George; Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008187	A1	20020131	WO 2001-US22813	20010719
WO 2002008187	C2	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2410682	AA	20020131	CA 2001-2410682	20010719
US 2002160962	A1	20021031	US 2001-909012	20010719
EP 1303487	A1	20030423	EP 2001-959041	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012666	A	20030610	BR 2001-12666	20010719
JP 2004513881	T2	20040513	JP 2002-514094	20010719
NZ 523781	A	20041029	NZ 2001-523781	20010719
ZA 2002010311	A	20040319	ZA 2002-10311	20021219
NO 2003000271	A	20030318	NO 2003-271	20030120
PRIORITY APPLN. INFO.:			US 2000-220107P	20000721
			WO 2001-US22813	20010719

GI



I



II

AB Novel peptides I [G, J, Y = independently H, alkyl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkoxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkyl-arylamino, arylamino, heteroarylamino, cycloalkylamino, and heterocycloalkylamino; Z = O, N, CH; W = null, CO, CS, SO2; R1 = COR5, B(OR)2; R5 = H, OH, OR8, NR9R10, CF3, C2F5, C3F7, CF2R6, R6, COR7; R7 = H, OH, OR8, CHR9R10, NR9R10; R6, R8-10 = independently H, alkyl, aryl, heteroalkyl, cycloalkyl, arylalkyl, peptide derivative, etc.; R, R2-4 = independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, etc.] and their pharmaceutically salts which have hepatitis C virus (HCV) protease inhibitory activity were prepared via solution or solid-phase peptide coupling methods. Thus, peptide II was prepared using solid-phase methods and showed a Ki value in the range of 0-100 nM for HCV protease inhibitory activity. This invention also discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease.

IC ICM C07D209-02
ICS C07D211-04; C07D233-56; C07D317-10; C07D319-04; C07D339-02; C07D339-08; C07C229-00; C07C233-05; C07C271-08; C07C271-32; A61K031-16; A61K031-27; A61K031-195; A61K031-357; A61K031-385; A61K031-403; A61K031-445; A61K031-4164

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 7, 63

ST peptide prepn NS3 serine protease inhibitor; hepatitis C virus treatment peptide

IT Antiviral agents
(pharmaceutical composition component; preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical composition component; preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

IT Peptides, preparation
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

IT Hepatitis C virus
(treatment; preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α, pharmaceutical composition component; preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

IT 36791-04-5, Ribavirin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition component)

IT 149885-80-3, NS3 protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

IT

393580-04-6P	393580-05-7P	393580-06-8P	393580-07-9P	393580-08-0P
393580-09-1P	393580-10-4P	393580-11-5P	393580-12-6P	393580-13-7P
393580-14-8P	393580-15-9P	393580-16-0P	393580-17-1P	393580-18-2P
393580-19-3P	393580-20-6P	393580-21-7P	393580-22-8P	393580-23-9P
393580-24-0P	393580-25-1P	393580-26-2P	393580-27-3P	393580-28-4P
393580-29-5P	393580-30-8P	393580-31-9P	393580-32-0P	393580-33-1P
393580-34-2P	393580-35-3P	393580-36-4P	393580-37-5P	393580-38-6P
393580-39-7P	393580-40-0P	393580-41-1P	393580-42-2P	393580-43-3P
393580-44-4P	393580-45-5P	393580-46-6P	393580-47-7P	393580-48-8P
393580-49-9P	393580-50-2P	393580-51-3P	393580-52-4P	393580-53-5P
393580-54-6P	393580-55-7P	393580-56-8P	393580-57-9P	393580-58-0P
393580-59-1P	393580-60-4P	393580-61-5P	393580-62-6P	393580-63-7P
393580-64-8P	393580-65-9P	393580-66-0P	393580-69-3P	393580-70-6P
393580-71-7P	393580-72-8P	393580-73-9P	393580-74-0P	393580-75-1P
393580-76-2P	393580-77-3P	393580-78-4P	393580-79-5P	393580-80-8P
393580-81-9P	393580-82-0P	393580-83-1P	393580-84-2P	393580-85-3P
393580-86-4P	393580-87-5P	393580-88-6P	393580-89-7P	393580-90-0P
393580-91-1P	393580-92-2P	393580-93-3P	393580-94-4P	393580-95-5P
393580-96-6P	393580-97-7P	393580-98-8P	393580-99-9P	393581-00-5P
393581-01-6P	393581-02-7P	393581-03-8P	393581-04-9P	393581-05-0P
393581-06-1P	393581-07-2P	393581-08-3P	393581-10-7P	393581-11-8P
393581-12-9P	393581-13-0P	393581-14-1P	393581-15-2P	393581-16-3P
393581-17-4P	393581-18-5P	393581-19-6P	393581-20-9P	393581-77-6P
393581-82-3P	393582-01-9P	393582-02-0P	393582-03-1P	393582-04-2P
393582-05-3P	393582-06-4P	393582-07-5P	393582-08-6P	393582-09-7P
393582-10-0P	393582-11-1P	393582-12-2P	393582-13-3P	393582-14-4P
393582-15-5P	393582-16-6P	393582-17-7P	393582-18-8P	393582-19-9P
393582-20-2P	393582-21-3P	393582-22-4P	393582-23-5P	393582-24-6P
393582-25-7P	393582-26-8P	393582-27-9P	393582-28-0P	393582-29-1P
393582-30-4P	393582-31-5P	393582-32-6P	393582-33-7P	393582-34-8P
393582-35-9P	393582-36-0P	393582-37-1P	393582-38-2P	393582-39-3P
393582-40-6P	393582-41-7P	393582-42-8P	393582-43-9P	393582-44-0P

393582-45-1P 393582-47-3P 393582-48-4P 393582-49-5P 393582-50-8P
393582-51-9P 393582-52-0P 393582-53-1P 393582-54-2P 393582-55-3P
393582-56-4P 393582-57-5P 393582-58-6P 393817-40-8P 394203-62-4P
394203-63-5P 394203-64-6P 394203-67-9P 394203-68-0P 394203-69-1P
394203-70-4P 394203-71-5P 394203-75-9P 394203-76-0P 394203-77-1P
394204-32-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

IT 91-00-9, Diphenylmethylamine 96-81-1 106-95-6, Allyl bromide, reactions 120-14-9 543-27-1, Isobutyl chloroformate 627-05-4, 1-Nitrobutane 652-40-4, 3,6-Difluorophthalic anhydride 870-46-2, tert-Butyl carbazate 2462-31-9 2762-32-5, 2-Piperazinecarboxylic acid 2900-27-8 2935-35-5 2999-46-4, Ethyl isocyanoacetate 4530-20-5 13211-31-9 35264-05-2 35661-40-6 35661-60-0 50305-43-6 53934-78-4 55447-00-2 55516-54-6 58438-04-3 98541-64-1 102410-65-1 109183-71-3 135112-28-6 143935-63-1 161321-36-4 270587-81-0 393581-87-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

IT 6485-52-5DP, resin-bound 41487-04-1P 58948-98-4P 60079-51-8P 64835-38-7P 76203-43-5P 137381-03-4P 143978-92-1P 150908-38-6P 151275-26-2P 166196-05-0P 166196-06-1P 181955-79-3P 276888-16-5P 276888-17-6P 276888-38-1P 276888-55-2P 276888-56-3P 367258-42-2P 367258-43-3P 367258-44-4P 367258-45-5P 367258-46-6P 367258-47-7P 367259-26-5P 367259-52-7P 367260-51-3P 371111-94-3P 371112-18-4P 371112-23-1P 393581-24-3P 393581-25-4P 393581-26-5P 393581-27-6P 393581-28-7P 393581-29-8P 393581-30-1P 393581-31-2P 393581-32-3P 393581-33-4P 393581-34-5P 393581-35-6P 393581-36-7P 393581-37-8P 393581-38-9P 393581-40-3P 393581-41-4P 393581-42-5P 393581-43-6P 393581-44-7P 393581-45-8P 393581-46-9P 393581-47-0P 393581-48-1P 393581-49-2P 393581-50-5P 393581-51-6DP, resin-bound 393581-52-7DP, resin-bound 393581-53-8P 393581-54-9P 393581-55-0P 393581-56-1P 393581-57-2P 393581-58-3P 393581-59-4P 393581-60-7P 393581-61-8P 393581-62-9P 393581-63-0P 393581-64-1P 393581-65-2P 393581-66-3P 393581-67-4P 393581-68-5P 393581-69-6P 393581-70-9P 393581-71-0P 393581-72-1P 393581-73-2DP, resin-bound 393581-74-3DP, resin-bound 393581-75-4DP, resin-bound 393581-76-5DP, resin-bound 393581-77-6DP, resin-bound 393581-78-7DP, resin-bound 393581-79-8DP, resin-bound 393581-80-1DP, resin-bound 393581-81-2DP, resin-bound 393581-82-3DP, resin-bound 393582-00-8P 394203-72-6P 394203-73-7P 394203-74-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'MARPATPREV' ENTERED AT 16:20:13 ON 17 FEB 2005
L10 STR



Page 1-A

~CO2H
21

Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 24 33
GGCAT IS MCY UNS AT 33
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L13 0 SEA FILE=MARPATPREV SSS FUL L10 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FILE 'HOME' ENTERED AT 16:20:30 ON 17 FEB 2005